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Circular Proteins:
Ring around with NOESY t
f
o
The secrets of ribosomally synthesized circular pro- g
teins are slowly revealed by gene sequencing and so- i
lution NMR studies of novel cyclotides and their pre- k
cursors, as demonstrated by Mulvenna et al. (2005) in a
this issue of Structure. e
Naturally occurring small circular peptides have long o
been known to exist in the bacterial world. The antibi- c
otic peptide gramicidin S and the potent immunosup- 2
pressive peptide cyclosporin A are two well-known ex- s
amples that are used as drugs. These cyclic bacterial f
peptides often contain uncommon amino acids, and g
they are biosynthetically produced by large peptide p
synthetases, rather than the standard ribosomal protein y
synthesis machinery. Cyclic peptides, and by extension p
circular proteins, have therefore remained a bit of an m
anomaly until the middle of the 1990’s, when the dis- c
covery of several ribosomally synthesized macro-cyclic f
proteins was reported. These proteins were all ex- c
tracted from plant material, and in addition to having t
a cyclic backbone, they were also found to contain a c
cystine-knot structure. The first cyclic cystine-knot pro- t
ttein to be fully structurally characterized was the pro-ein kalata B1 from the African plant Oldenlandia affinis
Saether et al., 1995) (Figure 1). The cystine-knot struc-
ure consists of three disulfide bonds, two of which
orm a ring structure in the peptide backbone, the third
ne passing in between these. This crosslinking pattern
ives the protein backbone a high stability and forces
t to adopt a β sheet structure. Such protein cystine-
not structures are rather common; for example, they
re also found in certain human growth hormones (Vitt
t al., 2001).
It is now known that kalata B1 is a typical example
f a large class of cyclic cystine-knot miniproteins,
ommonly referred to as the cyclotides (Craik et al.,
004). Similar proteins have been found in many plant
pecies, and there may well be several thousand dif-
erent cyclotides in plants (www.cyclotide.com). The
roup of cyclic proteins now also extends beyond
lants to the rhesus macaque monkeys, where a few
ears ago a highly unusual theta-defensin antimicrobial
eptide was uncovered (Tang et al., 1999). In fact, hu-
ans have a pseudogene for a highly similar protein
alled retrocyclin. The cyclic theta-defensin is distinct
rom the cyclotides as it has a ladder type disulfide
rosslinking pattern (Figure 1). Recently it was shown
hat the bacterial microcin J25 antimicrobial peptide
ontains a looped cyclic backbone structure involving
he side chain of a Glu residue and one end of the pro-
ein (Rosengren et al., 2003) (Figure 1). Clearly, there
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689Figure 1. Solution Structures of Some Cyclic Proteins Discovered in Recent Years
Clockwise from the top left: tricyclon A (the subject of the paper by Mulvenna et al. [2005] in this issue), the prototypic cyclotide kalata B1,
the theta-defensin RTD-1 from macaque monkeys, microcin J25 (a bacteriocin secreted by some enterobacteria); and SFTI-1 (a trypsin
inhibitor from sunflower seeds). All structures were determined by standard homonuclear NOESY NMR techniques, using proteins that were
not isotope labeled. In all cases the cyclic nature of the protein was confirmed by observing the nOe’s (nuclear Overhauser effects) between
the linking amino acids. (Figure provided courtesy of J. Mulvenna and D. Craik.)could be many more different types of circular proteins
than we currently think.
The notion that circular proteins would exist at all is
not immediately obvious. Genome sequencing efforts
have strongly reinforced the idea that all genes code
for proteins as a linear array of amino acids. Therefore,
a dedicated biosynthetic mechanism must exist to
achieve the end-to-end cyclization reaction. One can
think of nonenzymatic reactions similar to intein protein
splicing or special enzymes tailor-made to catalyze this
reaction, as is the case for the bacterial cyclic peptides.
In this issue of Structure, David Craik and his col-
leagues from the University of Queensland in Brisbane,
Australia, report on the structure of the novel circular
plant protein tricyclon A from Viola tricolor (Mulvenna
et al., 2005). The structure resembles that of other plant
cyclotides, but reveals a more extensive β sheet struc-
ture (Figure 1). Moreover, these investigators also
cloned and analyzed the sequence of the 22 kDa pre-
cursor protein that is posttranslationally processed to
give the cyclic protein. These data provide important
insights into the recognition sequences for the pro-
cessing of the linear array of amino acids, and such
work will eventually allow researchers to uncover the
protein cyclization mechanism.
One may wonder what the biological function of end-
to-end cyclization of the cyclotides is. The first thought
that comes to mind is that it removes the flexible N-
and C-terminal ends of the protein, which would be
substrates for exoproteases, thereby increasing the
stability of the protein. Likewise, the cystine-knot ties
down all the flexible regions in the remainder of the pro-
tein and thereby also makes the cyclotides resistant to
all endoproteases. Indeed, these proteins can be boiled
or treated with a broad range of proteases or denatur-
ing agents and survive unharmed, unless the disulfidebonds are reduced. The knot rather than the end-to-
end peptide bond appears to have the major effect on
the stability of the protein.
Finally it is worthwhile to consider potential applica-
tions of this unique class of circular proteins. Kalata B1
and some related proteins are known to play a role in
plant host defense, where they have anti-insecticidal
activity (Craik et al., 2004). Thus, improving insect resis-
tance of certain crops could be an area of future appli-
cation. Even though many of the cyclotides are some-
what hemolytic in vitro, they appear to have no negative
effects on humans. This property, taken together with
their phenomenal stability, may allow their use as stabi-
lizers of peptides with clinical potential. Many linear
peptides are known that have high potency and high
selectivity and great potential for clinical use. However,
the pharmaceutical industry has been reluctant to con-
sider such peptides as potential drugs, because they
are often rapidly degraded under in vivo conditions.
Consequently there is considerable interest in stabiliz-
ing their backbone. Some researchers have done this
by cyclizing peptides through chemical synthesis, lead-
ing to improved stability and activity in several cases
(e.g., Nguyen et al., 2005). Several groups have made
the linear peptide backbone indigestible to proteases
by utilizing unnatural D- or β-amino acids (Hunter et al.,
2005; Steer et al., 2002). This has created peptides that
are more protease resistant, but it has not always led
to an improved activity. Others have successfully stabi-
lized the peptide backbone and increased activity by
adding extra thioether linkages at specific places along
the backbone, as is done naturally in the lantibiotics, a
class of antimicrobial peptides produced by Lactoba-
cilli (Rew et al., 2002). By analogy, the cyclotides pro-
vide a unique nontoxic, rock-solid scaffold on which
such pharmaceutical peptides can potentially be
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690Sgrafted, thereby enhancing their “survivability” in vivo.
It might even be possible to graft two peptides simulta-
Cneously, one with a specific targeting sequence and the
(second with a designed pharmaceutical activity. Struc-
tural studies such as those reported by Mulvenna et al. H
a(2005) in this issue of Structure are important because
they reveal the optimal scaffold structures and graft M
sites to use for such applications. The fact that a sta- i
ble, highly disulfide crosslinked peptide derived from a N
marine toxin has recently been successfully brought to i
the market by Elan for the treatment of chronic pain
R(www.prialt.com) suggests that such applications of the
l
cyclotides are not far-fetched at all. Not only can suit- M
ably grafted cyclotides be used as pharmaceuticals,
Rbut end-to-end cyclization and stabilization of other
abioactive proteins and peptides may become feasible
Sas well. Thus, gramicidin and cyclosporin may be only
Nthe first examples of the successful pharmaceutical use
of cyclic peptides and proteins. S
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